US FDA Takes Steps To Simplify Combo Product Consultations
This article was originally published in Clinica
The US FDA says it is already simplifying access to its IT system, revising SOPs, updating its organizational charts and putting out more guidance documents, as recommended in an internal assessment (PDF) of its inter-center consultation process for combination products that was released by the agency Oct. 14.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.